Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 10/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19854533 | 0.97 | CYP1A2 (0.41) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19855984 | 0.96 | TP53 (0.40) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19855972 | 0.94 | CYP1A2 (0.39) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19854391 | 0.93 | CYP1A2 (0.39) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19853805 | 0.93 | CYP1A2 (0.39) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19854535 | 0.90 | CYP1A2 (0.37) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19854399 | 0.87 | CYP1A2 (0.35) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19854394 | 0.87 | CYP1A2 (0.35) | TP53MEN1HTTKMT2AEPHX1 | |
| SCHEMBL19854528 | 0.84 | ALDH1A1 (0.36) | TP53MEN1KMT2AEPHX1 | |
| SCHEMBL11709787 | 0.84 | TP53 (0.47) | TP53MEN1HTTKMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | TP53 1638/4885MEN1 73/4885HTT 4535/4885 |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | SP1, MBD2, PAXBP1 | TP53 1638/4885MEN1 73/4885HTT 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.